Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 10/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281102 | 0.84 | APLNR (0.34) | APLNRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13862140 | 0.84 | APLNR (0.34) | APLNRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8282772 | 0.79 | APLNR (0.42) | APLNRRXRAGRIN1GRIN2BPARP1 | |
| SCHEMBL8220973 | 0.79 | APLNR (0.42) | APLNRRXRAGRIN1GRIN2BPARP1 | |
| SCHEMBL8221396 | 0.77 | SOS1 (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8256522 | 0.77 | SOS1 (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5881157 | 0.74 | IDO1 (0.39) | APLNR | |
| SCHEMBL8282301 | 0.73 | IDO1 (0.37) | — | |
| SCHEMBL8257649 | 0.73 | KDM4E (0.36) | PARP1 | |
| SCHEMBL18192822 | 0.72 | APLNR (0.40) | APLNRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2007035542-A1 | 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | APLNR 1005/4885RXRA 350/4885GRIN1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.